EuroPCR25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Paris20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

Coronary revascularisation and TAVI: Before, during, after or never?

Commentary:

Professor Andrew BoyleJohn Hunter Hospital, Newcastle

Date of preparation May 2014 │BRI001132

Disclaimer

• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.

• These highlights have been suggested by a group of cardiologists who attended EuroPCR 2014, compiled by an external medical writer and sponsored by AstraZeneca. 

• AstraZeneca has obtained permission from EuroPCR, to utilise the selected content for educational purposes.

• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.  Presentations are intended for educational purposes only and do not replace independent professional judgement.

• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.

AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

• This presentation clearly summarised the clinical challenges in deciding if, and when, to revascularise patients with CAD who require TAVI, and supported the ‘common sense’ approach needed to resolve this issues in daily practice.

• The consensus at the session was that revascularisation is appropriate in severe CAD, but less severe disease might be better managed conservatively.

• The possibility that future coronary artery access could be compromised by TAVI should be considered when choosing the type of valve.

• Clinical trials including ACTIVATION will supplement the existing observational data and guide our practice.

Commentary: Professor Andrew Boyle